Actualités et vidéos - PERKINELMER INC.

Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. “Traditional IIFT processing can be tedious...

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and...

PerkinElmer Inc. (NYSE: PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the...

PerkinElmer Inc. (NYSE: PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a growth-oriented investment firm. The resulting new, high-growth Life Sciences and Diagnostics business, focused on developing and delivering novel scientific breakthroughs that will have a profound impact on improving global health, will share the PerkinElmer name with the Applied, Food and...

PerkinElmer Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023 at 2:15 p.m. ET. Steve Willoughby, senior vice president, investor relations & head of ESG, and Alan Fletcher, senior vice president, Life Sciences, will provide an update on the Company and its strategic priorities. To register, click here . A live...

PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the EnVision ® Nexus™ system , its fastest and most sensitive multimode plate reader to date, designed for demanding high-throughput screening (HTS) applications and to accelerate drug discovery efforts. The EnVision Nexus platform, with complementary microplates and optimized reagents from PerkinElmer’s drug discovery reagents portfolio, including proprietary HTRF ® and AlphaLISA...

PerkinElmer Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Cowen 43 rd Annual Health Care Conference and the Barclays Global Healthcare Conference. Cowen 43 rd Annual Health Care Conference – Boston, MA Monday, March 6, 2023 9:10 a.m. ET – Max Krakowiak, senior vice president and chief financial officer Barclays Global Healthcare Conference – Miami, FL Tuesday, March 14, 2023 8:00 a.m. ET – Prahlad...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 1, 2023. Fourth Quarter 2022 The Company reported GAAP earnings per share from continuing operations of $0.85, as compared to GAAP earnings per share from continuing operations of $1.45 in the same period a year ago. GAAP revenue for the quarter from continuing operations was $741 million, as compared to $1,028 million...

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 12, 2023 to all shareholders of record at the close of business on April 21, 2023. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a...

PerkinElmer Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio...

PerkinElmer Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 8:15 a.m. PT. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page . A replay of the presentation will be posted on the...

PerkinElmer, Inc. , (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. The validated and fully automatable...

PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has authorized the marketing of the EONIS™ SCID-SMA assay kit for in vitro diagnostic (IVD) use by certified laboratories for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. This is the first FDA authorized assay for SMA screening in newborns in the United States and is...

PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 2022 Stifel Healthcare Conference on Wednesday, November 16, 2022 at 9:10 a.m. ET in New York, NY. Max Krakowiak, senior vice president and chief financial officer at PerkinElmer, will provide an overview on the Company and its strategic priorities during a fireside chat. To register, click here . A live audio webcast will be available on the Latest...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 2, 2022. The Company reported GAAP earnings per share from continuing operations of $0.55, as compared to GAAP earnings per share from continuing operations of $0.94 in the same period a year ago. GAAP revenue for the quarter was $712 million, as compared to $861 million in the same period a year ago. GAAP operating income from...

PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today released its 2022 Environmental, Social and Governance (ESG) Report . The report describes progress on the Company’s previously stated goals , builds on the Company’s ESG commitments and summarizes its overall ESG strategy aimed at better supporting people and the planet. “Doing good by people and the planet is inextricably linked to our mission of innovating for a healthier world, and the...

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 10, 2023 to all shareholders of record at the close of business on January 20, 2023. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it will release its full third quarter 2022 financial results on November 8, 2022. Management will host a webcast the same day at 8:00 a.m. ET to discuss these results. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. The Company also announced that it anticipates organic revenue growth, non-COVID...

PerkinElmer, Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca ® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. The cutting-edge Cellaca PLX system, designed by the company’s Nexcelom unit, combines best-in-class image cytometer hardware,...

PerkinElmer’s (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select ™ reagent kit for the automation of its T-SPOT ® . TB test workflow for in vitro diagnostic (IVD) use by certified laboratories. The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs. The increased use of automation also improves blood sample logistics, as it...